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Key Points
• Angiogenesis preceded
infiltration of inflammatory
leukocytes during GVHD as
well as during experimental
colitis.
• Metabolic alterations and
cytoskeleton changes
occurred during early
angiogenesis, but classical
endothelial activation signs
were absent.
The inhibition of inflammation-associated angiogenesis ameliorates inflammatory
diseases by reducing the recruitment of tissue-infiltrating leukocytes. However, it is not
known if angiogenesis has an active role during the initiation of inflammation or if it
is merely a secondary effect occurring in response to stimuli by tissue-infiltrating
leukocytes. Here, we show that angiogenesis precedes leukocyte infiltration in
experimentalmodels of inflammatory bowel disease and acute graft-versus-host disease
(GVHD). We found that angiogenesis occurred as early as day12 after allogeneic
transplantation mainly in GVHD typical target organs skin, liver, and intestines, whereas
no angiogenic changes appeared due to conditioning or syngeneic transplantation. The
initiation phase of angiogenesis was not associated with classical endothelial cell (EC)
activationsigns, suchasVegfa/VEGFR112upregulationor increasedadhesionmolecule
expression. During early GVHD at day12, we found significant metabolic and
cytoskeleton changes in target organ ECs in gene array and proteomic analyses. These
modifications have significant functional consequences as indicated by profoundly
higher deformation in real-time deformability cytometry. Our results demonstrate that
metabolic changes trigger alterations in cell mechanics, leading to enhanced migratory and proliferative potential of ECs during the
initiation of inflammation. Our study adds evidence to the hypothesis that angiogenesis is involved in the initiation of tissue
inflammation during GVHD. (Blood. 2017;129(14):2021-2032)
Introduction
The number of allogeneic hematopoietic stem cell transplantations
(bone marrow transplantations, allo-BMT) performed worldwide is
increasing, as it often is the only curative treatment of hematologic
malignancies. Despite the maximum use of therapeutic options, many
patients die of acute graft-versus-host disease (GVHD), a systemic
inflammatory disease primarily attacking liver, skin, and intestines,
implicating a large unmet medical need for the development of novel
therapies. There is increasing evidence demonstrating that the vascular
endothelium can be used as a therapeutic target during GVHD.1,2 In
preclinical models as well as in patients, it has been demonstrated that
GVHD is associated with the formation of new blood vessels.2-5
Under pathological conditions,6-10 such as increased secretion of
proangiogenic mediators by inflammatory cells, tissue damage, or
oxygen and nutrient deficiency, endothelial cells (ECs) can rapidly
form new blood vessels in a tightly orchestrated process. It involves
the activation of ECs, the degradation of the extracellular matrix,
the vessel sprouting relying on migratory, guiding “tip” cells and
elongating, proliferative “stalk” cells, morphogenesis, and the vessel
stabilization by recruitment of pericytes. More recently, metabolic
processes in ECs11-13 involving fatty acid oxidation (FAO)14,15 and
glycolysis16,17 have been shown to be important for initial steps of
angiogenesis. Many of these processes can modulate angiogenic as
well as inflammatory regulatory mechanisms and activating or
targeting one can induce or modify the other,7,8 underlining the
importance of the crosstalk between angiogenesis and inflammation.
In animal models of inflammatory diseases, such as inflammatory
bowel disease (IBD) and GVHD, it has been demonstrated that the
inhibition of angiogenesis can be used therapeutically to reduce the
recruitment of tissue-infiltrating leukocytes.4,8,18,19 However, it is not
known if angiogenesis contributes to the initiation of inflamma-
tion or is a mere consequence of inflammation.20
We analyzed the role of angiogenesis during the initiation of
inflammation in experimentalmodels of IBDandGVHD,whichoccurs
after allogeneic hematopoietic stem cell transplantation.
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Materials and methods
Study design and statistics
Sample size for GVHD experiments was calculated by estimation of time
point–specific analyses based on the Student t test assuming 80% power and
0.05 2-sided level of significance. Experiments with at least 5 animals per group
(untreated [naı¨ve], conditioned-only [chemo], allogeneic [ALLO], or syngeneic
[SYN] transplanted mice) were performed 2 times.
Specific time points for analyses were chosen after initial time course
experiment. All collected data were used in statistical analyses, only excluding
animals that died before specific time points for data collection. Animals were
randomized, including equal distribution of weight status and mixed housing of
different transplanted animals. For subsequent analyses, transplant conditions
were encoded. All experiments were approved by the Regional Ethics
Committee for Animal Research (State Office of Health and Social Affairs,
Berlin).
Survival data were analyzed using the Kaplan-Meier method and compared
with the Mantel-Cox log-rank test. For all other data, the Student unpaired t test
(2-tailed) was used if not indicated differently. Normality tests and F test
confirmed Gaussian distribution and equality of variance between different
groups. Values are presented as mean 6 standard error of the mean (SEM).
Values ofP# .05were considered statistically significant.All statistical analyses
were performed using GraphPad Prism software (GraphPad Software Inc,
La Jolla, CA).
Mice
FemaleC57BL/6 (B6) (H2b), 129S2/SvPasCrl (129) (H2b), LP/J (H2b),B6D2F1
(BDF) (H2b/d), BALB/c (H2d), B6.Cg-Tg(CAG-DsRed*MST)1Nagy/J
(DsRed1B6) (H2b) mice (10–12 weeks old) were purchased from Charles
River Laboratories (Sulzfeld, Germany) and housed in the Charite´ University
Hospital Animal Facility. Mice were individually scored twice a week for 5
clinical parameters (posture, activity, fur, skin, and weight loss) on a scale from
0 to 2. Clinical GVHD score was assessed by summation of these parameters.
Survival was monitored daily.
GVHD experiments
For GVHD models LP/J→B6, B6→BDF, 129S2/Sv→B6, DsRed1B6→BDF,
recipient mice received intraperitoneal doses of 20 mg/kg per day busulfan
(Sigma-Aldrich, St. Louis, MO) for 5 days, followed by 100 mg/kg per day
cyclophosphamide (Sigma-Aldrich) for 3 days and were injected intravenously
with 1.5 3 107 bone marrow (BM) cells and 2 3 106 splenic T cells from
allogeneic and syngeneic donormice on day 0. For B6→BALB/c, recipientmice
received 900 cGy total body irradiation from a 137Cs source as a split dose with
a 3-hour interval and were injected intravenously with 5 3 105 BM cells and
13106 splenic T cells. BMwasflushed from the tibia and femur, and single-cell
suspension was prepared in phosphate-buffered saline (PBS)/2% fetal calf
serum/1 mmEDTA by gently passing through a 23-G needle and over a 70-mm
cell strainer (BD Biosciences, San Jose, CA). Splenic T-cell suspension was
obtained using the Pan T-cell Isolation Kit II (Miltenyi Biotec, Bergisch
Gladbach, Germany). For vascular endothelial growth factor A (VEGFA)
inhibition, LP/J→B6, B6micewere treated intraperitoneally 2 times aweekwith
5 mg/kg B20-4.1.1 (Genentech, South San Francisco, CA) or 5 mg/kg rat
immunoglobulin G2 (IgG2; Sigma-Aldrich). For VEGFR1/2 inhibition,
B6→BALB/c, BALB/c mice were treated intraperitoneally on days 0, 12,
14, 18, 110 with a combination of 800 mg DC101 and MF1 (ImClone
Systems, New York, NY) or with 800 mg rat IgG2.
Colitis (IBD) experiments
For colitis induction, 3% dextran sulfate sodium (DSS; MP Biomedicals, Santa
Ana, CA) was administered to B6 mice in drinking water. For DsRed colitis
experiments, B6mice received 1.53107BMcells fromDsRed1B6; at day140
after BMT,DsRed1BMchimeraswith.90%DsRed1 cells in bloodwere used
for DSS induction. For endothelial progenitor cell (EPC) experiments, B6 mice
received on the day of DSS induction intravenously 5 3 104 DsRed1EPCs,
which were fluorescence-activated cell sorted (FACS) (CD11b2, Ter1192,
c-Kit1, VEGFR21) from DsRed1B6 BM using a Bio-Rad S3 Cell
Sorter. Purity was 90% or higher.
Immune fluorescence staining
Tissue samples were cryoembedded in Tissue-Tek (Sakura Finetek, Alphen aan
denRijn,TheNetherlands).Sectionsmeasuring7mmwereacetonefixed(220°C),
blockedwith PBS/3%bovine serumalbumin /5% fetal calf serum, and stained
overnight at 4°Cwith primary ratmonoclonal antibodies (mAbs) against CD4
(H129.19, 1:500), CD8 (53-6.7, 1:500), CD11b (M1/70, 1:200), Gr1/Ly-6G
(RB6-8C5, 1:200), major histocompatibility complex-I (MHC-I)/H2kb
(AF6-88.5, 1:200), CD31 (MEC13.3, 1:400), panendothelial cell antigen
(MECA-32, 1:500) fromBDBiosciences andMHC-II (ER-TR3, 1:200) from
BMA Biomedicals (Augst, Switzerland); with hamster mAb against CD31
(2H8, 1:500) and rabbit polyclonalAb againstKi67 (PA5-19462, 1:200) from
Thermo Fisher Scientific (Waltham, MA). For visualization, 1:1000
secondary donkey anti-rat antibody Alexa Fluor 488 and goat anti-rabbit
antibody Alexa 555 (Life Technologies, Carlsbad, CA), goat anti-hamster Cy3
(Jackson ImmunoResearch, West Grove, PA), and nuclear counterstaining with
4’,6-diamidino-2-phenylindole (Sigma-Aldrich) were used. To determine
Marker1 area, 6 sections per sample were investigated with the 320/0.50
objective of BA410 epifluorescence microscope (Motic, Causeway Bay, Hong
Kong), and pictures were acquired with Moticam Pro 285B camera and Motic
Images Plus 2.0 Software fromMotic. Marker1 area to total area was quantified
with a predetermined threshold using Fiji Software (http://fiji.sc/Fiji). Increase in
vascular density was determined by elevated percentage of positive area of the
stained EC marker CD31 or MECA. For analysis of EC proliferation, 10 high-
power-field photographs per samplewere takenwith the340/0.75 objective of a
BA410 epifluorescence microscope. The number of Ki-671 cells in direct
contact with CD31 signal (Ki671 ECs) per high-power field was counted. For
Z-stacks, 21-mmsectionswere analyzedwith a Zeiss LSM700microscope (Carl
Zeiss AG, Oberkochen, Germany), and 20 sections per picture were taken.
Flow cytometry
Cells were washed twice and stained for 20 minutes at 4°C in PBS/0.5 mM
EDTA/0.5% bovine serum albumin with the following rat mAbs from BD
Biosciences: anti-CD31 (MEC13.3-APC and PE), anti-VEGFR2 (AVAS12a1-
PE), anti-ICAM (3E2-PE), anti-ckit (2B8-APC), anti-CD45 (30F11-PerCP-Cy5.5
and FITC), anti-CD11b (M1/70-APC-Cy7), anti-Ter119 (Ter119-PE-Cy7), anti-
H2kb (AF6-88.5-FITC). Samples were analyzed by BD FACSCanto II (BD
Biosciences) and FlowJo 7.6.5 Software (TreeStar Inc, Ashland, OR). In liver, ECs
were determined as Ter119-CD11b-CD45dim/2CD311 cells.
Quantitative real-time PCR
RNA and complementary DNA, obtained using the RNeasy Mini Kit (Qiagen,
Venlo, TheNetherlands) and theQuantiTect Reverse TranscriptionKit (Qiagen)
following the manufacturer’s instructions, were amplified (50°C, 2 minutes;
95°C, 10 minutes; 49 cycles of 95°C, 10 seconds; 60°C, 1 minute) on DNA
Engine Opticon (Bio-Rad, Hercules, CA) using the TaqMan Gene Expression
Master Mix (Life Technologies), and Vegfa, VEGFR2, Icam1, Vcam1, P- and
E-selectin primers and probe from BioTez GmbH (Berlin, Germany). Data
were analyzed with Opticon Monitor 3.1 analysis software (Bio-Rad) and the
comparative CT Method (DDCT Method).
EC isolation
Single-cell suspensions from liver and colon were generated via digestion at
37°C and continuous shaking with 2 mg/mL Collagenase D (Roche Diagnostics,
Rotkreuz,Switzerland) for45minutesand1mg/mLcollagenase IV(Sigma-Aldrich)
for60minutes, respectively.Cellswerepassedtwiceovera70-mmcell strainer.Liver
ECs were additionally enriched with gradient centrifugation using 30% Histodenz
(Sigma-Aldrich) according tomanufacturer’s instructions. For pure EC populations,
liver cells were magnetic-activated cell sorted (MACS)–isolated using CD146 liver
sinusoidal endothelial cells (LSEC) Microbeads (Miltenyi Biotec) after manufac-
turer’s instructions, and colon cells were FACS-sorted (CD11b2, CD45dim/2,
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Figure 1. Angiogenesis occurs exclusively in target organs and precedes leukocyte infiltration during GHVD. (A-C) Leukocyte infiltration: percentage of CD4-, CD8-,
CD11b-, and Gr1-positive area in GVHD-target organs colon, skin, and liver of allogeneic (ALLO) compared with syngeneic transplanted mice (SYN) 2 days (d12) after BMT.
Vascular density: percentage of CD31-positive area in colon and skin and EC number in liver of SYN and ALLO mice at day12 after BMT. (D) Time course of CD41 and CD81
lymphocyte infiltration. The red box marks first significant increase in CD4- and CD8-positive area in ALLO mice. Untreated (Naive) and only chemotherapy-conditioned
(Chemo) mice served as control and showed no infiltration. (E) Vascular density in nonclassical target organs skeletal and cardiac muscle and joints at day12, 17, and 115
after BMT. Untreated mice (Naive) served as control. Data pooled from 2 independent experiments (naive, chemo, n 5 5 per group; SYN, ALLO, n 5 10-12 per group). Error
bars indicate mean 6 SEM. *P , .05; **P , .01; ***P , .001; n.s., not significant by Student t test (2-tailed).
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CD311) using a Bio-Rad S3 cell sorter. Purity was checked via flow cytometry
analysis of ICAM1 and CD31.
Microarray analysis
Total RNA from colon EC was isolated with the mirVana miRNA Isolation
Kit (Life Technologies) and subjected to microarray analysis (GeneChip
MouseGene 2.0 STArray; Affymetrix). Obtained raw datawere normalized
with Expression Console Software and analyzed with Transcriptome
Analysis Console Software (Affymetrix) with the following parameters:
Fold Change (linear),22 or.2, analysis of variance P value (Condition
pair) , 0.05.
LC-MS/MS proteome analysis
At day12 after BMT, proteins from liver EC from allogeneic- and
syngeneic-transplanted mice were isolated and quantified by dimethylation
labeling,21,22 subjected to high through-put liquid chromatography tandem-
mass spectrometry (LC-MS/MS) analysis, andMS data were processed23,24
as described in detail in the supplemental Material and methods, available
on the Blood Web site. Quantitative ratios were calculated and normalized
byMaxQuant software package. R software (Version 3.0.0, www.r-project.
org) was used to calculate log2 ratios between syn- and allo-transplanted
groups, log10 of signal intensities, and P values of protein abundance
changes. P values, .05 were chosen as statistically significant. Normalized
ratios were used for differential expression analysis (up $1.3 or down
#0.44). Protein information (names, cellular localization, involved
functions, and pathways) were obtained from UniProtKB (http://www.
uniprot.org/).
Real-time deformability cytometry
Atday12afterBMT, liverECfromallogeneic- and syngeneic-transplantedmice
were isolated, and real-time deformability cytometry (RT-DC) measurements
were performed as previously described.25,26 For details on procedures, see the
supplemental Material and Methods.
Results
Angiogenesis precedes lymphocyte infiltration in acute GVHD
and in an experimental model of IBD
To shed light onto initialmechanismsof bothprocesses after allo-BMT,
we first determined the time course of angiogenesis (supplemental
Figure 1) as well as of leukocyte infiltration in a clinically relevant
murine MHC-matched, minor histocompatibility antigen–mismatched
GVHD model (LP/J [H2kb] →C57BL/6 [H2kb]).27 In allo-BMT
recipients, we found significant increased vascular density in the colon
and skin and significantly increased EC numbers in liver already on
day12 after BMT (Figure 1A-C). In contrast, infiltration of CD41 and
CD81 T cells into GVHD target organs did not occur until day17 in
colon and liver and until day115 in skin (Figure 1D). Also, the pan
myeloid cell marker CD11b as well as the neutrophil marker Gr-1/Ly-
6G did not show significant differences in the GVHD target organs at
day12, emphasizing that monocytes/macrophages/neutrophils as well
as lymphocytes did not infiltrate prior to the occurrence of angiogene-
sis (Figure 1A-C). Strikingly, conditioned mice and syn-BMT
recipients exhibited no change in vascular density, showing that
early angiogenesis was specific to GVHD and allo-BMT (supple-
mental Figures 1 and 2A,B). We confirmed the results with another
panendothelial cell marker MECA-32 (supplemental Figure 3) and
in 2 other murine GVHD models (129S2/SvPasCrl→C57BL/6 and
C57BL/6→B6D2F1) (supplemental Figures 4A,B and 5). Our
results demonstrate that angiogenesis is an initial event during
GVHD, whereas GVHD-associated infiltration of inflammatory
cells occurs secondarily.
We asked the question if initial angiogenesis is specific toGVHDor
likewise precedes infiltration of leukocytes in other inflammatory
diseases. In a standard model for IBD, the DSS-induced colitis
(supplemental Figure 6A) was found to have similar results to GVHD
experiments. CD311 vascular density was significantly increased
already at day11 after colitis induction (supplemental Figure 6B-D),
whereas infiltration of CD41, CD81, and CD11b1 cells was not
significantly increased in colon until day13 (supplemental Figure 6B,
C,E-G).
GVHD non–target organs showed no angiogenesis
and lymphocyte infiltration
To investigate if early angiogenesis occurs in the context of systemic
inflammation or is specific to GVHD target organs, we analyzed joints,
skeletal, and cardiac muscle. These organs are prone to angiogenesis
under pathological conditions,6,7,28 but they are typically not affected
by acuteGVHD.We found no significant change in vascular density as
well as no lymphocyte infiltration in the non–classical target organs of
allo-BMT vs syn-BMT recipients at day12 or any later time points
(Figures 1E; supplemental Figure 7).
No early incorporation of EPCs in experimental models of
GVHD and IBD
Next, we analyzed if the early increase in vascular density is dependent
on the proliferation of resident tissue ECs (angiogenesis) or on the
incorporation of BM-derived EPCs, termed vasculogenesis.8 We first
confirmed that at day12 after BMT, allo-BMT recipients showed
increased numbers of proliferating (Ki671) ECs in colon compared
with syn-BMT recipients (Figure 2A). To determine EPC incorpora-
tion, we transplanted B6D2F1 mice with DsRed1C57BL/6 BM cells
and T cells to induce GVHD.We could not detect costaining signals of
DsRed and CD31 in colon and skin of allo-BMT recipients at day12
(Figure 2B). Similarly,DsRed1BMchimeras aswell asC57BL/6mice
receiving EPCs from DsRed1C57BL/6 BM showed no significant
amount of CD311DsRed1 coexpressing cells in colon until day14
after induction of colitis (Figure 2C,D). Our data suggest that the initial
formation of blood vessels during GVHD and during experimental
colitis is due to the formation of new blood vessels from existing ones,
termed angiogenesis.
Effect of targeting angiogenesis in GVHD by blocking
Vegfa/VEGFR pathway
We aimed at identifying pathways that are relevant for early
angiogenesis during GVHD and initially investigated the Vegfa/
VEGFR112 axis.29 Based on our previous observation demonstrating
a reduction of GVHD due to inhibition of neovascularization by anti-
VE-cadherin antibodies,4 we performed therapeutic interventions with
monoclonal blocking antibodies. The anti-VEGFA antibody B20-4.1.1
had no significant effects on survival and GVHD scores during GVHD
(Figure 3A). VEGFR112-blocking by administration of MF1 and
DC101 led to inhibition of hematopoietic reconstitution (supplemen-
tal Figure 8) and decreased survival after allo-BMT (Figure 3B).
Furthermore, we found no consistent upregulation of Vegfa and
VEGFR2 expression levels in GVHD-target organs during the initiation
of GVHD (Figure 3C,D) or later time points (Figure 3E). Taken
together, our results argue against an important role of the Vegfa/
VEGFR2pathway for initiation of angiogenesis inGVHDtarget organs.
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6→B6D2F1). (C) Representative pictures of green-
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Z-stacks of colon samples at day14 after DSS induction
from colitis-bearing and control mice, which received
DsRed1 EPCs. Green A488-CD31 signal is vessel-
related. Scale bar, 30 mm (A-C). Error bar indicates
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Expression levels of inflammation-associated endothelial
activation markers in GVHD
Wenext investigated EC activation and adhesionmolecules during early
and established GVHD. ECs constitutively express MHC-I,30,31 which
did not change after transplantation (supplemental Figure 9A,B). In a
highly inflammatory environment at day115, we found a significant in-
crease inMHC-II1CD311 area in liver of allo-BMT recipients, whereas
in a leukocyte infiltration-free environment at day12, no MHC-II
upregulationoccurred (Figure3F).Typical for inflammatorydiseases,we
found increased expression levels of adhesionmolecules, such as Icam1,
Vcam1, E-, and P-selectin in GVHD target organs (supplemental
Figure 10) during established GVHD at day115. In sharp contrast, at
day12 MACS-isolated CD45dim1neg/CD11b2/CD311 liver ECs of
allo-BMT recipients (supplemental Figure 11A,B) showed significant
downregulation of gene expression levels of these markers compared
with syn-BMT recipients (Figure 3G).Our results demonstrate that initial
endothelial activation follows a different pattern as compared with
endothelial activation during established GVHD.
Metabolic and cytoskeleton changes in ECs lead to
higher deformability
To identify pathways during the initiation of angiogenesis in an unbiased
approach,weperformedmicroarrayanalysesofFACS-sorted colonECs
in allo-BMT recipients vs syn-BMT recipients at day12. Hierarchical
clustering revealed profound differences in gene expression in colon
ECsduring the initiation ofGVHD in allo-BMTvs syn-BMT(Figure 4A,
C). To detect relevant changes on protein level during the initiation of
angiogenesis, we performed LC-MS/MS proteome analyses of MACS-
isolated liverECsatday12after allo-BMTvssyn-BMT.Weidentified18
upregulated and 25 downregulated proteins (Figure 5A-C) showing
network connections (supplemental Figures 12 and 13). A list of
significant upregulated and downregulated genes and proteins is given in
supplemental Tables 1-4. Again, no upregulation of Vegfa and VEGFR2
was detected, and several adhesion molecules were downregulated,
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RNA level as well as on protein level (Figures 4B and 5B,C). In addition,
we found several differentially regulated cytoskeleton-associated
and -related genes (Tubal3, Myo3a, Scin, Ttll6) and proteins (RDX,
MYO6) in colon and liver EC in initial GVHD (Figures 4B and 5B,C).
To investigate if metabolic and cytoskeletal changes in ECs during
the initiation of GVHD have functional consequences, we measured
single-cell mechanical characteristics at high speed with RT-DC26
(Figure 6A). ECs from allo-BMT recipients and syn-BMT recipients at
day12 displayed heterogeneity in cell shape (Figure 6B). Liver ECs
from allo-BMT recipients showed a significantly higher deformation
(D 5 0.0547 6 0.0011) as compared with ECs from syn-BMT
recipients (D5 0.04516 0.0010) (Figure 6C-D) at day12 after BMT.
This deformation is attended by the overall softening of ECs during the
initiation of GVHD. The cell size was not affected (Figure 6D). In
addition to the observed downregulation of cell-cell contact proteins
and the upregulation of cytoskeleton-associated proteins (described
above), the EC softening indicates an enhanced migratory potential.
Discussion
It is well known that inflammatory diseases are associated with
angiogenesis. The proposed mechanism for this association is an
induction of angiogenesis by secreted mediators of tissue
infiltrating inflammatory cells.6,7 In this study, we provide novel
evidence on a primary involvement of angiogenesis in the initiation
of tissue inflammation prior to infiltration of inflammatory cells.
We demonstrate that angiogenesis precedes leukocyte infiltration
during inflammation in animal models of GVHD. We confirmed
our finding in an experimental model of IBD, implicating a broader
significance of our results surpassing the field of transplantation
biology.
Our current results add further data to the accumulating evidence on
the significant importance of endothelial function for the pathophysiology
of GVHD. Findings from preclinical models, demonstrating that GVHD
is associated with the formation of new blood vessels, were confirmed
in humans.2-5 Furthermore, endothelial pathology was specifically
connected to mortality in patients with GVHD.32,33 First mechanistic
insights in therapeutic targeting angiogenesis by inhibiting the endothelial
adhesion molecules VE-cadherin and av integrin in murine GVHD
models potentially opened a new field of GVHD treatment options.2-4 In
thepresent study,we found that initial angiogenesis specifically arose after
allo-BMT independently from syn-BMT or conditioning underlining the
particular role of angiogenesis for GVHD pathogenesis.
Our results can be used as rationale for the translational develop-
ment of anti-inflammatory therapies aimed at angiogenesis. With our
finding that certainmetabolic andcytoskeleton changes are involved in
the initiation of inflammatory angiogenesis, we provide potential
targets for anti-inflammatory therapies aimed at angiogenesis. Recent
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Figure 4. Microarray analysis of colon ECs reveals profound metabolic and cytoskeletal changes during initiation of angiogenesis in GVHD. (A) Hierarchical
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research has demonstrated that metabolic processes are linked to
increased proliferative activity and vessel sprouting.11-15,17,34-36
Inhibition of glycolysis by the 6-phosphofructo-2-kinase/fructose-
2,6-biphosphatase inhibitor 3-(3-pyridinyl)-1-(4-pyridinyl)-2-propen-
1-one (3PO)17,37 as well as inhibition of FAO by etomoxir15 showed
beneficial antiangiogenic effects in several inflammatory models.
Interestingly, FAO inhibitors such as ranolazine or perhexiline are
clinically available and showed good drug tolerability in humans.38
Glycolysis has been shown to be associated with remodeling of the
cytoskeleton during EC migration and angiogenesis.16,36 Accordingly,
we found several differentially regulated cytoskeleton-associated and
cytoskeleton-related genes and proteins in colon and liver EC in
initial GVHD. Cell shape alterations by the cytoskeletonwere shown
to be critical for various steps of angiogenesis.39 Cytoskeletal
remodeling–dependent elevated proliferation was previously shown
to soften cells in vitro.25,40 We used a novel method, termed RT-
DC,26 to demonstrate that cytoskeleton changes result in higher
deformability of ECs during the initiation of inflammation leading
to increased proliferation and migration potential. The endothe-
lial cytoskeleton can be efficiently targeted by microtubule
depolymerizing agents belonging to the large group of small molecular
weight vascular disrupting agents. Several of them, including the lead
compound disodium combretastatin A-4 3-O-phosphate, are currently
under clinical development for cancer.41-44 In addition, there are new
approaches to directly target ECs, eg, by a multimodular recombinant
protein, E-selectin-specific “sneaking ligand construct” 1 (SLC1),
which only binds to cytokine-activated ECs, providing the opportunity
to minimize toxicity and off-target effects.45 However, before trans-
lating our results into the clinical setting, functional analyses of
pathways and therapeutic targets in preclinical models are needed. In
addition, it has to be considered that the endothelium is damaged during
conditioning therapy and during later phases of GVHD. Possible
unwanted effects of antiangiogenic therapy on endothelial regeneration
in these settings have to be addressed prior to translation of such
therapeutic approaches.
The optimal schedule of an antiangiogenic treatment in inflamma-
tory diseases represents a challenging question.9 We showed that
angiogenesis occurred as early as day12afterBMT.Ourdata are in line
with previous observations demonstrating that angiogenesis can be a
dynamic and fast process during trauma, inflammation, and cancer
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growth.46,47 Under conditions requiring rapid angiogenesis, such as
wound healing, the microenvironment is quickly shifted, enabling
development of new vessels within days.48,49 As immune cell infiltration
is known to contribute to resistance against antiangiogenic drugs,50,51
starting a therapy prior to that could diminish these mechanisms as well
as inflammatory-associated side effects. In the setting of GVHD, it
offers the opportunity to initiate treatment early and potentially prevent
or initially minimize disease outbreak.
Our current data argue against an important role of the Vegfa/
VEGFR-1/2 pathway for GVHD pathophysiology. The role and
dynamics of VEGFdiffer in humanGVHD;whereas several studies
showed no change52 or even decreased53-55 circulating VEGFA
levels, Medinger et al5 detected an increase in VEGF1 megakar-
yocytes going in line with increased VEGF levels found by
Porkholm et al56 in pediatric GVHD patients. However, this study
only applied a univariate analysis. In a univariate and multivariate
study by Luft et al, VEGF levels were not found to be predictive in
GVHD; only during refractory GVHD were angiopoetin2/VEGFA
ratios higher.57 Detected differences in VEGF levels may occur due to
different posttransplant time points of determination, different measure-
ment assays, VEGF sources (eg, serum in patients vs organ biopsies in
our study), or varying GVHD progression. For example, severe course
of GVHD was found associated with activation and infiltration of
macrophages,58-61 which are known to be a source of VEGF.62-64 The
clinical setting in GVHD is variable due to different drug applications,
particularly preexisting diseases or treatments, which modify a growth
factor pathway in many ways. These findings underline the importance
of identifying VEGF-independent pathways and treatment options
during pathogenic angiogenesis.29,65
During inflammatory activation, ECs can upregulate MHC-II
and also exhibit antigen-presenting properties as described in
human allografts66 and various inflammatory diseases, eg, rheumatoid
arthritis.67 In a highly inflammatory tissue environment during
established GVHD, we found increased expression levels of adhesion
molecules responsible for leukocyte trafficking and endothelial
activation in GVHD target organs, which confirms previous
knowledge.68,69 In contrast, we found that initial endothelial activation
during GVHD is not associated with upregulation of adhesion
molecules and MHC-II, which is in line with results from patient
biopsies during earlyGVHD.70,71A similarECphenotypewith reduced
expression of adhesion molecules has been demonstrated in malignant
tumors during pathological angiogenesis.72-74 Our data demonstrate
that early angiogenesis during the initiationof inflammationdiffers from
the EC activation pattern, which is found during established tissue
inflammation.
In conclusion, we provide novel insights into the initiation
phase of inflammation and in GVHD pathophysiology. Our study
adds evidence to the hypothesis that angiogenesis is involved in the
initiation of tissue inflammation during inflammatory diseases. Our
results strengthen the scientific rationale, and provide potential
therapeutic targets, for development of antiangiogenic therapies to
inhibit inflammation.
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